Evidenced by improved performance of other serological cancer biomarkers, mostly single organ targeted, such as fucosylated α- AFP for HCC17,54, glycosylated PSA for prostate cancer17, and CA19-9/ THBS2 marker for pancreatic cancer22, simultaneous targeting ofCS with its modified core proteins were focused on to develop the pan-cancer biomarker in our study. This evidence concerns the gene THBS2 and cancer.